Between evidence and commerce - the case of sufentanil sublingual tablet systems
- PMID: 29219168
- PMCID: PMC5814728
- DOI: 10.1111/anae.14037
Between evidence and commerce - the case of sufentanil sublingual tablet systems
Keywords: conflict of interest; pain; sublingual sufentanil.
Comment on
-
Narrative review: the promotion of gabapentin: an analysis of internal industry documents.Ann Intern Med. 2006 Aug 15;145(4):284-93. doi: 10.7326/0003-4819-145-4-200608150-00008. Ann Intern Med. 2006. PMID: 16908919 Review.
References
-
- Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Annals of Internal Medicine 2006; 145: 284–93. - PubMed
-
- van de Donk T, Ward S, Langford R, Dahan A. Pharmacokinetics and pharmacodynamics of sublingual sufentanil for postoperative pain management. Anaesthesia 2018; 73: 231–7. - PubMed
-
- Drazen JM, de Leeuw PW, Laine C, et al. Toward more uniform conflict disclosures–the updated ICMJE conflict of interest reporting form. New England Journal of Medicine 2010; 363: 188–9. - PubMed
-
- Thompson DF. Understanding financial conflicts of interest. New England Journal of Medicine 1993; 329: 573–6. - PubMed
-
- Rosenbaum L. Understanding bias–the case for careful study. New England Journal of Medicine 2015; 372: 1959–63. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources